Thomas T.
- Country
- Germany
- Department
- Universitätshautklinik
Research Overview
- Evaluation of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab in Advanced Melanoma: A Randomized, Double-Blind, Phase 2/3 Study
- Phase 3 Study of Naporafenib and Trametinib Versus Physician's Choice in NRAS Mutant Cutaneous Melanoma
- Continuation Study of Encorafenib, Binimetinib, and Ribociclib in Patients with Solid Tumors: Safety and Tolerability Assessment
Data & Insights
Has run more than one trial at 67 of 195 partner sites.
Specializations
Oncology Focus
The investigator specializes in treating various forms of solid tumors, with particular expertise in cutaneous melanoma research and therapeutic development.
- Advanced Melanoma Treatment
- NRAS Mutation Studies
- Metastatic Disease Management
Their research encompasses both early-stage and advanced therapeutic approaches for solid tumor management.
Targeted Therapies
The investigator focuses on novel therapeutic combinations including targeted molecular treatments and bispecific T cell-engaging therapies.
- TCER® Technology Applications
- Combination Treatment Strategies
- Novel Drug Development
Their work involves evaluating innovative therapeutic approaches for treatment-resistant cancers.
Clinical Development
The investigator conducts research in treatment optimization and safety evaluation of novel therapeutic agents.
- First-in-Human Studies
- Drug Safety Assessment
- Treatment Response Monitoring
Their expertise extends to determining optimal dosing strategies and evaluating therapeutic efficacy.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.